Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Inmune Bio (INMB) Other Operating Expenses (2019 - 2025)

Inmune Bio (INMB) has disclosed Other Operating Expenses for 6 consecutive years, with $16.5 million as the latest value for Q2 2025.

  • Quarterly Other Operating Expenses rose 13777.31% to $16.5 million in Q2 2025 from the year-ago period, while the trailing twelve-month figure was $16.5 million through Dec 2025, up 14777.48% year-over-year, with the annual reading at $16.5 million for FY2025, N/A changed from the prior year.
  • Other Operating Expenses hit $16.5 million in Q2 2025 for Inmune Bio, up from $119000.0 in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $16.5 million in Q2 2025 to a low of -$425000.0 in Q1 2022.
  • Historically, Other Operating Expenses has averaged $2.3 million across 5 years, with a median of -$8000.0 in 2021.
  • Biggest five-year swings in Other Operating Expenses: tumbled 5212.5% in 2022 and later soared 13777.31% in 2025.
  • Year by year, Other Operating Expenses stood at -$8000.0 in 2021, then crashed by 5212.5% to -$425000.0 in 2022, then soared by 78.82% to -$90000.0 in 2023, then soared by 232.22% to $119000.0 in 2024, then skyrocketed by 13777.31% to $16.5 million in 2025.
  • Business Quant data shows Other Operating Expenses for INMB at $16.5 million in Q2 2025, $119000.0 in Q2 2024, and -$8000.0 in Q1 2024.